Vol. 3 No. 2 (2023)
Reimbursement Reviews

Tezepelumab (Tezspire)

Published February 6, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Tezepelumab (Tezspire), 210 mg, 110 mg/mL solution for subcutaneous injection.
  • Indication (proposed): indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.